<div id="readability-page-1"><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li></ul>An announcement from CSL ( (AU:CSL) ) is now available. CSL Limited has announced an update on its ongoing share buy-back program, revealing that a total of 2,773,525 ordinary fully paid securities have been repurchased before the previous day, with an additional 46,950 securities bought back on the previous day. This buy-back initiative is part of CSL’s strategy to manage its capital structure effectively, potentially enhancing shareholder value and reinforcing its market position. The most recent analyst rating on (AU:CSL) stock is a Buy with a A$256.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page. More about CSL CSL Limited operates in the biotechnology industry, focusing on the development and delivery of innovative biotherapies and influenza vaccines. The company is a global leader in plasma-derived therapies and operates in various markets worldwide, providing essential medicines to patients with rare and serious conditions. YTD Price Performance: -33.39% Average Trading Volume: 1,150,052 Technical Sentiment Signal: Sell Current Market Cap: A$89.23B Learn more about CSL stock on TipRanks’ Stock Analysis page.</div>

CSL Limited announced an update on its share buy-back program, repurchasing 2,773,525 ordinary securities, with an additional 46,950 bought back recently. This initiative aims to manage capital structure and enhance shareholder value. CSL operates in biotechnology, focusing on biotherapies and vaccines. The stock has a Buy rating with a A$256.00 price target, despite a YTD price performance of -33.39%.

CSL Limited Updates on Share Buy-Back Progress